Latest News
From Digital Transformation to Operational Intelligence in Healthcare
Healthcare has never really had a technology problem. The greater challenge has been turning technology into better ways of working. Over the past decade, healthcare organizations have invested heavily in electronic health records, digital services, automation,...
Latest News
Fatty Pancreas Disorder and the New Era of Integrated Obesity Management
Obesity is increasingly recognized as a chronic systemic disease characterized not only by excess adiposity but also by progressive dysfunction of multiple organs. Recent advances have shifted attention from body weight alone toward ectopic fat deposition as a major...
Rethinking Biomedical Research in the Age of AI
The paradox of modern biomedical research Biomedical research has never generated so much knowledge, and researchers have never struggled so much to keep pace with it. PubMed now indexes more than 40 million references drawn from roughly 26,000 journals[1]....
Australia Marks 40 years of Daffodil Day on Thursday 20 August
Cancer Council calls on Australians to help fund the next 40 years of breakthroughs One of Australia's most iconic and enduring fundraising campaigns, Daffodil Day, will return on Thursday 20 August 2026, marking 40 years of Australians coming together to support...
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
Beyond Tolvaptan: The Next Generation of ADPKD Therapies
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...
What Trauma Taught Me That Medical School Never Did
Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Weekly News Roundup | 17 August 2026
Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...
Crohn’s, Colitis and Conception: Building a Family with IBD
When treating individuals with inflammatory bowel disease (IBD), either Crohn's disease or ulcerative colitis, I’m often asked: "Will this stop me having children?". Given that IBD affects around 180,000 Australians and is typically first diagnosed between the ages of...
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints
Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Clinical Trials Roundup | 14 Aug 2026
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
Modeling T Cell Dysfunction: New Frontiers in Immunometabolism
While cancer immunotherapies—particularly immune checkpoint blockades (ICBs)—have transformed clinical oncology, primary and acquired resistance remain major hurdles in solid tumors. Mounting evidence reveals that this non-responsiveness is deeply tied to the...
Beyond Tolvaptan: The Next Generation of ADPKD Therapies
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...
What Trauma Taught Me That Medical School Never Did
Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...
CAR-T Therapy Explained: A Plain-English Guide
CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Weekly News Roundup | 17 August 2026
Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...
Crohn’s, Colitis and Conception: Building a Family with IBD
When treating individuals with inflammatory bowel disease (IBD), either Crohn's disease or ulcerative colitis, I’m often asked: "Will this stop me having children?". Given that IBD affects around 180,000 Australians and is typically first diagnosed between the ages of...
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints
Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Clinical Trials Roundup | 14 Aug 2026
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
From Laboratory to Market: Risk Planning for Life Science Companies
The UK life sciences sector is entering an important phase of growth. The Government's Life Sciences Sector Plan sets an ambition for the UK to become the leading life sciences economy in Europe by 2030 and the third globally by 2035. It also reports that the sector...
Biopharma VC Funding in H1 2026: Megarounds Mask an Early-Stage Squeeze
Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data...
Featured Articles
Further News
Organ Digital Twins: Inside Imperial College London’s Research
Organ digital twins have moved from mathematical curiosity to funded national priority. Imperial College London now sits close to the centre of that shift. Researchers there have built more than 3,800 anatomically accurate virtual hearts. They have also begun an NHS...
Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS
Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...
Kidney Care’s $2.5 Billion Timing Problem
Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...
Blood Supplies Set For Vital Boost as Donation Rules Are Updated
Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...
In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained
In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...
Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines
Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...
Beyond Weight Loss: What Emerging GLP-1 Research Reveals
For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...
GLP-1 Side Effects: What the Evidence Actually Says
An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...
Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic
The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...
Asia Is No Longer Pharma’s Factory. It Is Becoming the Source
Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...
Catching Pediatric Strabismus: When It Is More Than a Glare Reaction
Monocular eye closure in bright sunlight glare can often be interpreted as a benign photic response in pediatric patients. However, the behavior may point to an early or intermittent manifestation of binocular vision dysfunction such as intermittent exotropia....
Regulation Is Pushing European Medtechs to Streamline Clinical Trials
Europe’s changing macroeconomic and regulatory environment is prompting the medtech industry to rethink clinical processes and technologies. New insights reveal focus on establishing a unified digital foundation as medtech companies look to optimise data strategy,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.